Neumora Therapeutics Inc
(NMRA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 143,361 | 374,038 | 240,993 |
| Marketable Securities | 165,430 | 79,944 | 130,941 |
| TOTAL | $314,055 | $478,279 | $387,955 |
| Non-Current Assets | |||
| PPE Net | 1,140 | 1,790 | 2,411 |
| Investments And Advances | 0 | 9,845 | 23,511 |
| Other Non-Current Assets | 1,777 | 6,281 | 12,357 |
| TOTAL | $2,917 | $17,916 | $38,279 |
| Total Assets | $316,972 | $496,195 | $426,234 |
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 3,307 | 337 | 7,147 |
| Accrued Expenses | 24,593 | 21,257 | 11,536 |
| Other current liabilities | 133 | 139 | 1,644 |
| TOTAL | $29,886 | $25,111 | $23,697 |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 22 | 2,008 | 5,700 |
| TOTAL | $22 | $2,008 | $5,700 |
| Total Liabilities | $29,908 | $27,119 | $29,397 |
| Shareholders' Equity | |||
| Shares Outstanding, K | 161,979 | 158,886 | N/A |
| Common Shares | 16 | 16 | 3 |
| Retained earnings | -947,221 | -703,434 | -467,509 |
| Other shareholders' equity | 62 | -76 | 842,913 |
| TOTAL | $287,064 | $469,076 | $396,837 |
| Total Liabilities And Equity | $316,972 | $496,195 | $426,234 |